Verition Fund Management
SVA

Verition Fund Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Verition Fund Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-14,413
Closed -$75K – 602
2014
Q4 		$75K Buy
14,413
+901
+7% +$4.59K 0.02% 305
2014
Q3 		$65K Sell
13,512
-562
-4% -$3.02K 0.01% 664
2014
Q2 		$79K Buy
+14,074
New +$85.5K 0.01% 613

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Verition Fund Management's SVA Position: Q1 2015 in Review

Verition Fund Management sold out of Sinovac Biotech, Ltd (SVA) in Q1 2015, closing a stake of 14,413 shares — an estimated $75K sold.

Verition Fund Management first reported a position in SVA in Q2 2014 and held it in 3 quarters. The position peaked at $79K in Q2 2014. 40 funds tracked by Wall St. Rank hold SVA as of Q1 2015.

  • Verition Fund Management reported no remaining Sinovac Biotech, Ltd position as of Q1 2015 after selling out during the quarter.
  • Verition Fund Management sold 14,413 Sinovac Biotech, Ltd shares in Q1 2015, an estimated $75K.
  • Verition Fund Management first reported a position in Sinovac Biotech, Ltd in Q2 2014 and held it in 3 quarters.
  • Verition Fund Management's Sinovac Biotech, Ltd position peaked at $79K in Q2 2014.
  • 40 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2015.

Based on Verition Fund Management's 13F filing for Q1 2015, filed 15 May 2015.